Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.
CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Syst Rev. 2024 Jun 1;13(1):147. doi: 10.1186/s13643-024-02554-9.
Personalised prevention aims to delay or avoid disease occurrence, progression, and recurrence of disease through the adoption of targeted interventions that consider the individual biological, including genetic data, environmental and behavioural characteristics, as well as the socio-cultural context. This protocol summarises the main features of a rapid scoping review to show the research landscape on biomarkers or a combination of biomarkers that may help to better identify subgroups of individuals with different risks of developing specific diseases in which specific preventive strategies could have an impact on clinical outcomes. This review is part of the "Personalised Prevention Roadmap for the future HEalThcare" (PROPHET) project, which seeks to highlight the gaps in current personalised preventive approaches, in order to develop a Strategic Research and Innovation Agenda for the European Union.
To systematically map and review the evidence of biomarkers that are available or under development in cancer, cardiovascular and neurodegenerative diseases that are or can be used for personalised prevention in the general population, in clinical or public health settings.
Three rapid scoping reviews are being conducted in parallel (February-June 2023), based on a common framework with some adjustments to suit each specific condition (cancer, cardiovascular or neurodegenerative diseases). Medline and Embase will be searched to identify publications between 2020 and 2023. To shorten the time frames, 10% of the papers will undergo screening by two reviewers and only English-language papers will be considered. The following information will be extracted by two reviewers from all the publications selected for inclusion: source type, citation details, country, inclusion/exclusion criteria (population, concept, context, type of evidence source), study methods, and key findings relevant to the review question/s. The selection criteria and the extraction sheet will be pre-tested. Relevant biomarkers for risk prediction and stratification will be recorded. Results will be presented graphically using an evidence map.
Population: general adult populations or adults from specific pre-defined high-risk subgroups; concept: all studies focusing on molecular, cellular, physiological, or imaging biomarkers used for individualised primary or secondary prevention of the diseases of interest; context: clinical or public health settings.
https://doi.org/10.17605/OSF.IO/7JRWD (OSF registration DOI).
个性化预防旨在通过采用针对个体生物特性(包括遗传数据)、环境和行为特征以及社会文化背景的靶向干预措施来延迟或避免疾病的发生、进展和复发。本方案总结了快速范围综述的主要特点,以展示有关生物标志物或生物标志物组合的研究现状,这些标志物或生物标志物组合可能有助于更好地识别具有特定疾病不同风险的个体亚组,针对这些个体亚组,特定的预防策略可能对临床结局产生影响。本综述是“个性化预防未来医疗保健路线图”(PROPHET)项目的一部分,旨在突出当前个性化预防方法中的差距,以便为欧盟制定战略研究和创新议程。
系统地绘制和综述在癌症、心血管和神经退行性疾病中可用或正在开发的生物标志物的证据,这些生物标志物可用于一般人群中的个性化预防,无论是在临床环境还是公共卫生环境中。
正在并行进行三项快速范围综述(2023 年 2 月至 6 月),基于具有一些调整以适应每种特定情况(癌症、心血管或神经退行性疾病)的共同框架。将在 Medline 和 Embase 上搜索 2020 年至 2023 年期间的出版物。为了缩短时间框架,将由两名审查员对 10%的论文进行筛选,并且只考虑英语论文。两名审查员将从所有入选论文中提取以下信息:来源类型、引用详情、国家、纳入/排除标准(人群、概念、背景、证据来源类型)、研究方法以及与审查问题相关的关键发现。选择标准和提取表将进行预测试。将记录与风险预测和分层相关的相关生物标志物。结果将使用证据图以图形方式呈现。
人群:一般成年人群或来自特定预先定义的高危亚组的成年人;概念:所有专注于分子、细胞、生理或成像生物标志物的研究,这些标志物用于感兴趣疾病的个体化一级或二级预防;背景:临床或公共卫生环境。